Pneumocystis jirovecii Pneumonia


Risk

  • PJP is a respiratory infection seen in immunocompromised pts, usually associated with a CD4 cell count <500/μL.

  • Can affect pts with both acquired and congenital immunodeficiency syndromes.

  • Seen in both males and females and all age groups.

  • Often associated with chronic HIV infection, particularly if not treated with HAART.

Perioperative Risks

  • Respiratory failure often necessitating mechanical ventilatory support with high airway pressures even when ventilating with low tidal volumes; often accompanied by severe dyspnea independent of gas exchange.

  • Hemodynamic instability associated with induction of anesthesia, initiation of positive pressure ventilation.

  • Pneumothoraces.

  • Persistent expiratory airflow reduction after resolution of acute infection.

  • Bronchiectasis, lung cysts.

  • Often associated with other comorbidities related to immune deficiency.

Worry About

  • Progressive respiratory failure with diffuse bilateral interstitial infiltrates.

  • Pneumothoraces, either spontaneous or associated with positive-pressure ventilation.

  • Persistent pulm dysfunction.

  • Common cause of nonproductive cough, dyspnea, fevers in immunosuppressed pt

  • Associated with other opportunistic infections, particularly CMV and Candida albicans esophagitis.

  • Toxicity from therapy with sulfa antimicrobials, including methemoglobinemia, anemia, leukopenia, and severe skin rashes.

  • High incidence of drug resistance.

Overview

  • Indolent disease; can progress to severe respiratory failure.

  • May be cause for nonproductive cough in high-risk pt.

  • High incidence of spontaneous pneumothoraces.

  • Extrapulmonary sites of Pneumocystis infection are rare.

  • May be associated with other infections (tuberculosis, bacterial, viral, fungal) and malignancies (Kaposi sarcoma, lymphoma) in immunosuppressed pts.

Etiology

  • P. jiroveci (previously carinii ), originally characterized as a parasite, is now classified as a fungus.

  • Organisms reside in the lungs, usually as latent infection; activated in an immunosuppressed host.

  • High prevalence of antibodies to P. jirovecii in nonimmunosuppressed humans, suggesting that most individuals are “colonized” early in life.

  • Human-to-human transmission has not been documented.

You're Reading a Preview

Become a Clinical Tree membership for Full access and enjoy Unlimited articles

Become membership

If you are a member. Log in here